Literature DB >> 24667179

Procollagen type 1 amino-terminal propeptide (P1NP) and risk of hip fractures in elderly Norwegian men and women. A NOREPOS study.

T E Finnes1, C M Lofthus2, H E Meyer3, E F Eriksen2, E M Apalset4, G S Tell5, P Torjesen6, S O Samuelsen7, K Holvik7.   

Abstract

The current study aimed to assess a possible association between the bone turnover marker procollagen type 1 amino-terminal propeptide (P1NP) and future hip fractures in elderly Norwegian men and women and to elucidate the relation between P1NP, bone mineral density and 25-hydroxyvitamin D (25(OH)D). Men and women aged 71 to 77 from two population based health studies in Norway (1999-2001) were followed for a median period of 7.3 years with respect to hip fractures. The study was designed as a case-cohort study. P1NP and 25(OH)D were analysed in frozen serum samples obtained at baseline in hip fracture patients (n=340) and in randomly selected sex stratified sub-cohorts. Bone mineral density was measured by dual-energy X-ray absorptiometry (DXA) in a subset of participants. Cox proportional hazards regression with inverse probability weighting and robust variance was performed. No significant correlation between 25(OH)D and P1NP was found. A negative correlation between P1NP and BMD was observed in women (Rho=-0.36, p=0.001). A similar trend was observed in men. No association between quartiles of P1NP and rate of subsequent hip fractures was found. Spline analyses suggested a higher rate of hip fracture at P1NP levels above 60 μg/L in both men and women. A higher hip fracture rate, which was independent of BMD, was also indicated in women with very low levels of P1NP.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone turnover marker; Elderly; Hip fractures; Osteoporosis; Procollagen type 1 amino-terminal propeptide

Mesh:

Substances:

Year:  2014        PMID: 24667179     DOI: 10.1016/j.bone.2014.03.010

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

Review 1.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

2.  Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case-Control Study in the Women's Health Initiative.

Authors:  Carolyn J Crandall; Sowmya Vasan; Andrea LaCroix; Meryl S LeBoff; Jane A Cauley; John A Robbins; Rebecca D Jackson; Douglas C Bauer
Journal:  J Bone Miner Res       Date:  2018-06-19       Impact factor: 6.741

3.  Foxf2 represses bone formation via Wnt2b/β-catenin signaling.

Authors:  Tomoyuki Tanaka; Akira Takahashi; Yutaka Kobayashi; Masanori Saito; Sun Xiaolong; Chen Jingquan; Yoshiaki Ito; Tsuyoshi Kato; Hiroki Ochi; Shingo Sato; Toshitaka Yoshii; Atsushi Okawa; Peter Carlsson; Hiroyuki Inose
Journal:  Exp Mol Med       Date:  2022-06-06       Impact factor: 12.153

4.  Bone Turnover Status: Classification Model and Clinical Implications.

Authors:  Alexander Fisher; Leon Fisher; Wichat Srikusalanukul; Paul N Smith
Journal:  Int J Med Sci       Date:  2018-02-01       Impact factor: 3.738

5.  Age-related Reference Intervals for Total Collagen-I-N-terminal Propeptide in Healthy Korean Population.

Authors:  Jun-Il Yoo; Ae-Ja Park; Yong Kwan Lim; Oh Joo Kweon; Jee-Hye Choi; Jae Hyuk Do; Sunjoo Kim; Youngri Kim; Yong-Chan Ha
Journal:  J Bone Metab       Date:  2018-11-30

6.  Dimethandrolone Undecanoate, a Novel, Nonaromatizable Androgen, Increases P1NP in Healthy Men Over 28 Days.

Authors:  Arthi Thirumalai; Fiona Yuen; John K Amory; Andrew N Hoofnagle; Ronald S Swerdloff; Peter Y Liu; Jill E Long; Diana L Blithe; Christina Wang; Stephanie T Page
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

7.  Lower serum P1NP/βCTX ratio and hypoalbuminemia are independently associated with osteoporotic nonvertebral fractures in older adults.

Authors:  Alexander Fisher; Wichat Srikusalanukul; Leon Fisher; Paul N Smith
Journal:  Clin Interv Aging       Date:  2017-07-19       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.